NCT00573989 · OUTCOME

Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I)

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer · Source last updated 2019-01-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: mg
Interval / dispersion: Not reported
Time frame: 56 Days

What was measured

Dose at which 100% of participants tolerated the dose

Groups in this outcome

Erlotinib

Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Erlotinib	27

Reported measurements

Source class 1

Values in mg · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Erlotinib	125	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
125

denoms

counts
group Id
OG000
value
27
units
Participants

description

Dose at which 100% of participants tolerated the dose

groups

description
Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy
id
OG000
title
Erlotinib

param Type

NUMBER

reporting Status

POSTED

time Frame

56 Days

title

Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I)

type

PRIMARY

unit Of Measure

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice